source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 12d ago↗ source
- 2026 IPO class blooms again as BlossomHill, Latigo set sights on NasdaqEighteen companies have gone public this year so far, putting 2026 on pace to record the highest number of IPOs since the pandemic-driven high of 2021.BioSpace · 12d ago↗ source
- Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trialA phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on…Fierce Biotech · 12d ago